Vocacapsaicin is being developed as a novel, water-soluble prodrug of capsaicin that allows for infiltration into surgical sites. In vitro and in vivo there is evidence for rapid conversion to capsaicin. In moderately acidic solutions vocacapsaicin is stable at room temperature, thus allowing for dose formulation preparation. This work, along with data showing clinical efficacy in surgical patients demonstrates that vocacapsaicin allows for efficient delivery of capsaicin, a TRPV1 agonist, to the surgical site. Vocacapsaicin is currently in Phase 3 clinical development for the treatment of postsurgical pain.
Learning Objectives:
Upon completion of this presentation, the audiance will be introduced to the need for treatment of post surgical pain and the potential role of a TPV1-agonist.
Upon completion of this presentation, the audiance will understand the prodrug design of vocacapsaicin, a pH labile prodrug of capsaicin.
Upon completion of this presentation, the audiance will be able to discuss the in vitro and in vivo results.
